I. MODIFIED AGREEMENTS | |||
Biotech Co.* (Country; Symbol) |
Pharma Co. (Country) |
Change from original agreement |
Terms/Details (Date) |
| | |||
Astex |
AstraZeneca plc (UK) |
Extended research collaboraration in which Astex will continue to apply its high-throughput X-ray crystallography technology to obtain crystal structures of human cytochrome P450s alone and in complex with AstraZeneca's compounds |
Financial terms were not disclosed (7/7) |
|
|
|
|
Compugen Ltd. (Israel; CGEN) |
Novartis Pharma AG (Switzerland) |
Extended license of Compugen's LEADS platform for another year |
Compugen will design a genome-wide collection of DNA probes for Novartis (6/16) |
|
|
|
|
Cubist Pharmaceuticals Inc. (CBST) |
Eli Lilly & Co. |
Modified agreement in which Cubist purchased a reduction in the royalties payable to Lilly on netsales of Cidecin |
Cubist acquired rights from Lilly in 1997; it will issue to Lilly $8M in stock and the global royalty obligation will be reduced by 1% (7/2) |
|
|
|
|
Cypress Bioscience Inc. (CYPB) |
Pierre Fabre Medicament SA (France) |
Modified milnacipran agreement |
Cypress exercised its option for an exclusive license to develop and sell any milnacipran product for all indications in the U.S. and Canada; Pierre Fabre will continue to have the right to manufacture raw material needed for milnacipran products, and will receive 1M shares of Cypress stock and a warrant to purchase another 300,000 shares (6/9) |
|
|
|
|
Genedata AG* (Switzerland) |
Novartis Pharma AG (Switzerland) |
Extended multiyear collaboration to provide a license to Genedata's PathoLead Edition of its Phylosopher platform as well as consulting services to the Novartis Institutes for BioMedical Research Inc. |
Financial terms were not disclosed (6/18) |
|
|
|
|
Genentech Inc. (NYSE:DNA) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Exercised option in which Roche gains non-U.S. rights to Genentech's Avastin |
Genentech retains rights in the U.S. (7/8) |
|
|||
GPC Biotech AG (Germany; FSE:GPC) |
Altana Pharma AG (Germany) |
Expanded collaboration and license agreement to include GPC's LeadCode technology to evaluate compounds in the public domain as well as Altana Pharma compounds |
GPC will receive committed funding for the license, transfer and implementation of LeadCode for use at the Altana Research Institute, which will be established through the collaboration; GPC could receive more than $15M in milestone payments, and Ariad will receive license payments of $1M over the next 20 months, as well as additional license fees (6/13) |
|
|
|
|
Isis Pharmaceuticals Inc. (ISIS) |
Eli Lilly and Co. |
Modified manufacturing agreement for Affinitak |
Lilly agreed to waive a $21M manufacturing loan repayment from Isis; Isis agreed to let Lilly out of its Affinitak supply obligations; the changes were made following Affinitak's disappointing Phase III non-small-cell lung cancer trial (6/5) |
|
|
||
Scynexis |
Merck & Co. Inc. |
Extended multiyear research collaboration to discover and develop anti-infective compounds |
Scynexis will use its Medchem-Factory and Heos technologies to help accelerate the identification of drugs active against Merck's screening targets; Merck would receive exclusive worldwide rights to any products developed through the collaboration; Scynexis would receive milestone payments on developed products and royalties on sales (7/16) |
|
|
||
Sequitur |
Procter & Gamble Pharmaceuticals |
Renewed agreement to provide P&G access to Sequitur's functional genomics technology |
The agreement also was expanded to include additional therapeutic areas (5/22) |
|
|||
Speedel Group* (Switzerland) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Exercised option for Speedel to license exclusive worldwide rights for the full development and commercialization to SPP301 from Roche |
Speedel paid an undisclosed milestone for its part of the agreement (5/22) |
|
|||
II. TERMINATED AGREEMENTS | |||
CeNeS Pharmaceuticals plc (UK; LSE:CEN) |
Elan Corp. plc (Ireland) |
Terminated joint venture that was created in 2001 to develop M6G to treat pain |
CeNeS will fund the clinical development of M6G by itself; no more funding will be available to CeNeS under the convertible loan stock arrangements entered in June 2001 (6/18) |
|
|||
Cytogen Corp. (CYTO) |
Berlex Laboratories (U.S. affiliate of Schering AG; Germany) |
Terminated agreement for rights to the cancer pain product Quadramet |
Cytogen regained rights to Quadramet and agreed to make an up-front payment and issue royalties on future sales; it regained North and South American marketing rights (6/16) |
|
|||
Generex Biotechnology Corp. (Canada; GNBT) |
Eli Lilly and Co. |
Terminated development and license agreement for a buccal delivery of insulin |
Both parties are working on terms for Lilly to continue to supply a specified amount of insulin for Generex's further development work; Generex regains all rights to the buccal spray drug delivery technology (5/27) |
|
|||
Gilead Sciences Inc. (GILD) |
Bukwang Pharm. Ind. Co. Ltd. (South Korea) |
Terminated licensing agreement related to clevudine, which is in development for chronic hepatitis B |
The collaboration began in February 1998 between Bukwang and Triangle Pharmaceuticals Inc., which was acquired by Gilead last year (6/24) |
|
|||
PPL Therapeutics plc (UK; LSE:PTH) |
Bayer Healthcare |
Terminated agreement for the development of alpha-1- antitrypsin |
Bayer decided to stop the project and re- group due to a delay between Phase II and Phase III trials and the absence of a manufacturing site (6/19) |
|
|||
RxKinetix |
Elan Corp. plc (Ireland) |
Terminated agreement in which RxKinetix acquired exclusive development rights to RK-0202, an oral rinse for oral mucositis that is in Phase II development |
RxKinetix will pay a royalty to the joint venture on certain revenues (6/3) |
|
|||
Vernalis |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Terminated option on Vernalis' adenosine A2A antagonist research program in depression |
Vernalis now has control over the pro- grams, which target a range of indications including Parkinson's disease and depression (6/5) |
|
|||
XOMA Ltd. (XOMA) |
Baxter Healthcare Corp. |
Terminated agreement for Neuprex |
XOMA will receive a one-time, $10M payment after terminating the license and supply agreements with Baxter (7/8) |
|
|||
|
| |||
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange. | |||
